ArticleEJHaem2023

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.

Paul G Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.